These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9619535)

  • 21. A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome.
    Ciampelli M; Leoni F; Lattanzi F; Guido M; Apa R; Lanzone A
    Hum Reprod; 2002 Mar; 17(3):647-53. PubMed ID: 11870117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.
    Guido M; Romualdi D; Suriano R; Giuliani M; Costantini B; Apa R; Lanzone A
    Hum Reprod; 2004 Mar; 19(3):534-9. PubMed ID: 14998947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
    Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study.
    Pontikis C; Yavropoulou MP; Toulis KA; Kotsa K; Kazakos K; Papazisi A; Gotzamani-Psarakou A; Yovos JG
    J Womens Health (Larchmt); 2011 Jun; 20(6):971-6. PubMed ID: 21671782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
    Anastasiou OE; Canbay A; Fuhrer D; Reger-Tan S
    Arch Gynecol Obstet; 2017 Aug; 296(2):363-371. PubMed ID: 28608050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin sensitivity in women with polycystic ovary syndrome.
    Vrbíková J; Cibula D; Dvoráková K; Stanická S; Sindelka G; Hill M; Fanta M; Vondra K; Skrha J
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2942-5. PubMed ID: 15181081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
    Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
    Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of oral glucose administration on plasma growth hormone levels in women with polycystic ovary syndrome.
    Tropeano G; Barini A; Caroli G; Carfagna P; Vuolo IP; Novelli P; Rossodivita A; Lucisano A; Lanzone A
    Fertil Steril; 1997 Dec; 68(6):987-91. PubMed ID: 9418684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic β-cell dysfunction in polycystic ovary syndrome.
    Malin SK; Kirwan JP; Sia CL; González F
    J Clin Endocrinol Metab; 2014 Jan; 99(1):322-9. PubMed ID: 24203060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β cell function and insulin resistance in lean cases with polycystic ovary syndrome.
    Pande AR; Guleria AK; Singh SD; Shukla M; Dabadghao P
    Gynecol Endocrinol; 2017 Nov; 33(11):877-881. PubMed ID: 28704124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia.
    Ciotta L; De Leo V ; Farina M; Pafumi C; La Marca A ; Cianci A
    Gynecol Obstet Invest; 2001; 51(1):44-50. PubMed ID: 11150875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome.
    Aydin K; Arusoglu G; Koksal G; Cinar N; Aksoy DY; Yildiz BO
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):588-92. PubMed ID: 24730585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.
    González F; Rote NS; Minium J; Kirwan JP
    J Clin Endocrinol Metab; 2006 Jan; 91(1):336-40. PubMed ID: 16249279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome.
    Lanzone A; Fulghesu AM; Guido M; Ciampelli M; Caruso A; Mancuso S
    Hum Reprod; 1994 Dec; 9(12):2242-6. PubMed ID: 7714138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretin levels in polycystic ovary syndrome.
    Vrbikova J; Hill M; Bendlova B; Grimmichova T; Dvorakova K; Vondra K; Pacini G
    Eur J Endocrinol; 2008 Aug; 159(2):121-7. PubMed ID: 18511472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.
    Holte J; Bergh T; Berne C; Wide L; Lithell H
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2586-93. PubMed ID: 7673399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.